Press Releases

Press Releases
Date Title and Summary View
Mar 3, 2017 UNVEIL evaluated the efficacy and safety of oral OTEZLA at 16 weeks in patients with moderate plaque psoriasis who were naïve to systemic and biologic therapy SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that findings from ongoing clinical t...
Mar 1, 2017 PDUFA date set for Aug. 30, 2017 SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals (NASDAQ:AGIO) today announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene's New Drug Application (NDA) for enasidenib ...
Feb 27, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company's website at www.cel...
Feb 24, 2017 Oral REVLIMID® is the first and only medicine licensed in Europe for use as post-autologous stem cell transplantation maintenance therapy in multiple myeloma The new indication expands the availability of REVLIMID® across the disease continuum of multiple myeloma ...
Feb 23, 2017 - Jacqualyn Fouse, Ph.D., to retire from Celgene effective June 30, 2017 and will not stand for reelection to the Celgene Board of Directors - Scott Smith to be promoted to President and Chief Operating Officer, effective April 1, 2017 - Terrie Curran to be promoted to President, G...
Feb 22, 2017 REVLIMID is the first and only treatment approved for maintenance following auto-HSCT Updated data from two large, randomized, controlled studies demonstrated median progression-free survival (PFS) advantages of 3.8 and 1.9 years, respectively, in favor of patients receiving REVLIMID comp...
Feb 17, 2017 Study met its primary endpoint in reducing annualized relapse rate (ARR) and measured secondary endpoints, compared to interferon (IFN) β-1a (Avonex®) Safety and tolerability consistent with phase II studies Confirmatory phase III RADIANCE trial data expected in Q2 of 201...
Feb 3, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at an upcoming investor conference where Celgene management will provide an overview of the Company. The conference will be webcast live and will be available in the Investor Relations section of the Company's website at www.celgen...
Jan 27, 2017 REVLIMID® is the first and only medicine granted positive CHMP opinion for post-Autologous Stem Cell Transplantation (ASCT) maintenance therapy in MM The new indication expands the availability of REVLIMID® across the disease continuum of MM ...
Jan 26, 2017 Net Product Sales $2.98B in Q4:16; Increased 17% Y/Y Net Product Sales $11.18B in 2016; Increased 22% Y/Y 2017 Guidance for Net Product Sales and Diluted EPS SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) reported opera...
PDF
Add to Briefcase
FirstPrevious ...
5
... NextLast
Add to Briefcase = add release to Briefcase